{"id":30775,"date":"2022-06-13T17:59:00","date_gmt":"2022-06-13T09:59:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30775"},"modified":"2025-03-27T18:04:31","modified_gmt":"2025-03-27T10:04:31","slug":"meta-pharmaceuticals-secures-14-8-million-to-advance-immuno-metabolism-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30775","title":{"rendered":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development"},"content":{"rendered":"\n<p>Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.<\/p>\n\n\n\n<p><strong>Company Background and Progress<\/strong><br>META Pharmaceuticals was incubated by Forcefield Ventures and XtalPi in August 2021. The company boasts founders from prestigious institutions such as Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. Focused on autoimmune diseases, META is advancing three potential first-in-class programs, with plans to file for clinical trials in the US and China in 2024.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,20,740,3937,25,696],"class_list":["post-30775","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-finance","tag-meta-bright","tag-meta-pharmaceuticals","tag-potential-first-in-class","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30775\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30775\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T09:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T10:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development\",\"datePublished\":\"2022-06-13T09:59:00+00:00\",\"dateModified\":\"2025-03-27T10:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775\"},\"wordCount\":151,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Finance\",\"Meta Bright\",\"META Pharmaceuticals\",\"Potential first-in-class\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30775#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30775\",\"name\":\"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-13T09:59:00+00:00\",\"dateModified\":\"2025-03-27T10:04:31+00:00\",\"description\":\"Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30775\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30775#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30775","og_locale":"en_US","og_type":"article","og_title":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30775","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-13T09:59:00+00:00","article_modified_time":"2025-03-27T10:04:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30775#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30775"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development","datePublished":"2022-06-13T09:59:00+00:00","dateModified":"2025-03-27T10:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30775"},"wordCount":151,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Finance","Meta Bright","META Pharmaceuticals","Potential first-in-class","Xtalpi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30775#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30775","url":"https:\/\/flcube.com\/?p=30775","name":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-13T09:59:00+00:00","dateModified":"2025-03-27T10:04:31+00:00","description":"Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30775#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30775"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30775#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"META Pharmaceuticals Secures $14.8 Million to Advance Immuno-Metabolism Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30775"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30775\/revisions"}],"predecessor-version":[{"id":30777,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30775\/revisions\/30777"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}